We serve Chemical Name:4-[1,2,4]Triazol-1-yl-butyric acid CAS:158147-52-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![4-[1,2,4]Triazol-1-yl-butyric acid](https://a.dearchem.com/CAS2/158147-52-5.png)
Chemical Name:4-[1,2,4]Triazol-1-yl-butyric acid
CAS.NO:158147-52-5
Synonyms:4-(1,2,4-triazol-1-yl)butanoic acid
Molecular Formula:C6H9N3O2
Molecular Weight:155.15500
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:391.5ºC at 760mmHg
Density:1.34g/cm3
Index of Refraction:1.599
PSA:68.01000
Exact Mass:155.06900
LogP:0.14290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-(1,2,4-triazol-1-yl)butanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(1,2,4-triazol-1-yl)butanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(1,2,4-triazol-1-yl)butanoic acid Use and application,4-(1,2,4-triazol-1-yl)butanoic acid technical grade,usp/ep/jp grade.
Related News: The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 4-[1,2,4]Triazol-1-yl-butyric acid manufacturer Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 4-[1,2,4]Triazol-1-yl-butyric acid supplier The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 4-[1,2,4]Triazol-1-yl-butyric acid vendor Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 4-[1,2,4]Triazol-1-yl-butyric acid factory Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 4-[1,2,4]Triazol-1-yl-butyric acid manufacturer Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 4-[1,2,4]Triazol-1-yl-butyric acid supplier The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 4-[1,2,4]Triazol-1-yl-butyric acid vendor Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 4-[1,2,4]Triazol-1-yl-butyric acid factory Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.
